| Literature DB >> 20347509 |
Davinder Kumar1, Vikramjeet Judge, Rakesh Narang, Sonia Sangwan, Erik De Clercq, Jan Balzarini, Balasubramanian Narasimhan.
Abstract
A series of benzylidene hydrazides (1-20) was synthesized and tested, in vitro, for antibacterial, antifungal and antiviral activities. The microbial screening results indicated that compounds having chloro and nitro substituents were the most active ones. The antiviral evaluation depicted that compounds 9 and 19 were active against Vesicular stomatitis virus (VSV) in HeLa cell cultures. QSAR investigations indicated that the multi-target QSAR model was effective in describing the antimicrobial (antibacterial and antifungal) activity over the one-target QSAR models. Further the mt-QSAR model indicated that the topological parameters, second order molecular connectivity index ((2)chi) and third order Kier's alpha shape index (kappaalpha(3)) are effective in describing the antimicrobial activity of synthesized hydrazides. Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20347509 PMCID: PMC7127590 DOI: 10.1016/j.ejmech.2010.03.002
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514
Scheme 1Synthetic route followed to obtain target compounds from aliphatic acids.
Scheme 2Synthetic route followed to obtain target compounds from aromatic acids.
Physicochemical characteristics of synthesized benzylidene hydrazides.
| Comp. | Mol. formula | M. wt. | Mp/Bp+ (°C) | % Yield | |
|---|---|---|---|---|---|
| C19H30N2O | 302 | 60–64 | 0.62 | 67.8 | |
| C21H34N2O | 330 | 65–69 | 0.43 | 58.3 | |
| C23H38N2O | 358 | 93–97 | 0.65 | 62.3 | |
| C25H42N2O | 386 | Semisolid | 0.57 | 59.3 | |
| C13H14N2O | 214 | Semisolid | 0.72 | 45.1 | |
| C16H14N2O | 250 | 92–96 | 0.76 | 40.0 | |
| C15H14N2O | 238 | Semisolid | 0.62 | 79.0 | |
| C15H14N2O | 238 | 220–224 | 0.82 | 54.3 | |
| C16H16N2O3 | 284 | 228–232 | 0.83 | 74.0 | |
| C 14H10N4O5 | 314 | 205–209 | 0.65 | 78.3 | |
| C19H29N2OCl | 336 | 63–67 | 0.71 | 40.0 | |
| C21H33N2OCl | 364 | 69–73 | 0.73 | 84.0 | |
| C23H37N2OCl | 392 | 98–102 | 0.72 | 63.0 | |
| C25H41N2OCl | 420 | 108–112 | 0.78 | 22.3 | |
| C13H13N2OCl | 248 | 170–174+ | 0.71 | 61.1 | |
| C16H13N2OCl | 284 | Semisolid | 0.50 | 80.2 | |
| C15H13N2OCl | 272 | 155–159 | 0.75 | 40.1 | |
| C15H13N2OCl | 272 | 241–245+ | 0.85 | 42.2 | |
| C16H15N2O3Cl | 318 | 240–244 | 0.88 | 80.0 | |
| C14H9N4O5Cl | 384 | 235–239 | 0.89 | 58.0 |
Mobile phase – Toluene:Chloroform (7:3).
Ethyl acetate:Hexane (6:4).
Antibacterial and antifungal potential (μM/mL) of synthesized benzylidene hydrazides.
| Comp. | pMICsa | pMICbs | pMICec | pMICca | pMICan | pMICb | pMICf | pMICam |
|---|---|---|---|---|---|---|---|---|
| 1.38 | 1.30 | 1.38 | 1.21 | 1.21 | 1.35 | 1.21 | 1.30 | |
| 1.42 | 1.42 | 1.36 | 1.24 | 1.24 | 1.40 | 1.24 | 1.34 | |
| 1.46 | 1.46 | 1.50 | 1.76 | 0.86 | 1.47 | 1.31 | 1.41 | |
| 1.49 | 1.49 | 1.79 | 2.09 | 1.20 | 1.59 | 1.65 | 1.61 | |
| 1.23 | 1.23 | 1.23 | 0.93 | 1.54 | 1.23 | 1.24 | 1.23 | |
| 1.30 | 1.30 | 1.30 | 1.90 | 1.60 | 1.30 | 1.75 | 1.48 | |
| 1.28 | 1.28 | 1.28 | 1.88 | 1.58 | 1.28 | 1.73 | 1.46 | |
| 1.28 | 1.28 | 1.28 | 1.34 | 1.88 | 1.28 | 1.61 | 1.41 | |
| 1.36 | 1.36 | 1.36 | 1.96 | 1.66 | 1.36 | 1.81 | 1.54 | |
| 1.40 | 1.40 | 1.40 | 1.70 | 1.70 | 1.40 | 1.70 | 1.52 | |
| 1.43 | 1.43 | 1.80 | 1.73 | 1.43 | 1.55 | 1.58 | 1.56 | |
| 1.47 | 1.47 | 1.47 | 1.12 | 1.12 | 1.47 | 1.12 | 1.33 | |
| 1.50 | 1.49 | 1.50 | 2.10 | 1.27 | 1.50 | 1.69 | 1.57 | |
| 1.53 | 1.53 | 1.53 | 1.83 | 1.29 | 1.53 | 1.56 | 1.54 | |
| 1.30 | 1.30 | 1.30 | 1.60 | 1.50 | 1.30 | 1.55 | 1.40 | |
| 1.36 | 1.36 | 1.36 | 1.76 | 1.76 | 1.36 | 1.76 | 1.52 | |
| 1.34 | 1.34 | 1.34 | 1.34 | 1.51 | 1.34 | 1.43 | 1.37 | |
| 1.34 | 1.34 | 1.34 | 1.61 | 1.61 | 1.34 | 1.61 | 1.45 | |
| 1.41 | 1.41 | 1.41 | 2.01 | 1.56 | 1.41 | 1.79 | 1.56 | |
| 1.45 | 1.45 | 1.45 | 2.05 | 1.60 | 1.45 | 1.83 | 1.60 | |
| S.D. | 0.08 | 0.08 | 0.15 | 0.35 | 0.25 | 0.10 | 0.22 | 0.11 |
| Std. | 2.61 | 2.61 | 2.61 | 2.64 | 2.64 | 2.61 | 2.64 | 2.62 |
Ciprofloxacin.
Fluconazole.
Standard deviation.
MBC/MFC values of synthesized benzylidene hydrazides.
| Comp. | MBC/MFC (μM/mL) | ||||
|---|---|---|---|---|---|
| >0.166 | >0.166 | 0.041 | >0.166 | >0.166 | |
| >0.152 | >0.152 | >0.152 | >0.152 | >0.152 | |
| >0.139 | 0.139 | >0.139 | >0.139 | >0.139 | |
| 0.129 | <0.129 | 0.064 | <0.129 | 0.03 | |
| >0.233 | >0.233 | 0.058 | >0.233 | >0.233 | |
| >0.200 | >0.200 | 0.050 | >0.200 | >0.200 | |
| >0.210 | 0.052 | >0.210 | >0.210 | >0.210 | |
| >0.210 | 0.210 | 0.052 | >0.210 | >0.210 | |
| 0.088 | 0.044 | 0.177 | 0.011 | 0.022 | |
| >0.159 | 0.159 | >0.159 | 0.159 | 0.079 | |
| >0.148 | 0.148 | 0.009 | >0.148 | >0.148 | |
| >0.137 | >0.137 | 0.034 | >0.137 | >0.137 | |
| >0.127 | 0.031 | 0.031 | >0.127 | >0.127 | |
| >0.119 | 0.029 | >0.119 | >0.119 | 0.059 | |
| >0.201 | 0.050 | 0.100 | >0.201 | >0.201 | |
| 0.176 | 0.088 | >0.176 | >0.176 | >0.176 | |
| >0.183 | 0.045 | 0.045 | >0.183 | >0.183 | |
| 0.045 | 0.183 | 0.045 | >0.183 | 0.183 | |
| >0.157 | 0.039 | >0.157 | 0.019 | >0.157 | |
| >0.130 | 0.065 | >0.130 | >0.130 | >0.130 | |
| Std. | 0.019 | 0.019 | 0.019 | 0.040 | 0.040 |
Values of selected descriptors used in the regression analysis.
| Comp. | log | MR | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | Te | LUMO | HOMO | Ele.E | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.708 | 93.608 | 15.88 | 13.89 | 10.83 | 8.70 | 8.16 | 5.78 | 0.49 | 0.17 | 20.05 | 18.97 | 13.57 | 11.21 | 10.83 | 1.76 | 1568 | −3581.09 | −0.13 | −8.84 | 4.38 | −23877.40 | |
| 6.500 | 102.810 | 17.30 | 15.30 | 11.83 | 9.70 | 8.86 | 6.49 | 0.49 | 0.17 | 22.04 | 20.96 | 15.45 | 12.98 | 11.83 | 1.73 | 2067 | −3893.06 | −0.21 | −9.24 | 2.39 | −27346.00 | |
| 7.293 | 112.012 | 18.71 | 16.72 | 12.83 | 10.70 | 9.57 | 7.20 | 0.49 | 0.17 | 24.04 | 22.96 | 17.34 | 14.77 | 12.83 | 1.71 | 2662 | −4204.59 | −0.32 | −8.96 | 2.59 | −30530.90 | |
| 8.086 | 121.214 | 20.13 | 18.13 | 13.83 | 11.70 | 10.28 | 7.90 | 0.49 | 0.17 | 26.04 | 24.96 | 19.25 | 16.59 | 13.83 | 1.69 | 3361 | −4516.26 | −0.32 | −8.96 | 2.59 | −33750.50 | |
| 3.149 | 68.212 | 11.64 | 9.13 | 7.83 | 5.00 | 6.04 | 3.03 | 0.49 | 0.16 | 14.06 | 12.47 | 7.66 | 5.79 | 7.83 | 1.84 | 567 | −2589.03 | −0.57 | −8.75 | 4.71 | −14019.40 | |
| 3.834 | 77.988 | 13.34 | 10.36 | 9.34 | 5.96 | 7.62 | 3.89 | 0.70 | 0.25 | 15.39 | 13.31 | 7.34 | 4.94 | 9.34 | 1.39 | 896 | −2972.83 | −0.54 | −8.80 | 4.74 | −18470.90 | |
| 3.893 | 72.786 | 12.79 | 10.13 | 8.75 | 5.71 | 7.44 | 3.98 | 0.90 | 0.40 | 14.41 | 12.59 | 6.18 | 3.84 | 8.75 | 1.46 | 713 | −2845.59 | −0.35 | −8.83 | 4.58 | −16783.40 | |
| 3.893 | 72.786 | 12.79 | 10.13 | 8.75 | 5.71 | 7.43 | 3.98 | 0.90 | 0.40 | 14.41 | 12.59 | 6.18 | 3.84 | 8.75 | 1.46 | 724 | −2845.60 | −0.39 | −8.82 | 5.00 | −16734.30 | |
| 2.920 | 80.671 | 15.08 | 11.87 | 10.22 | 6.34 | 8.43 | 4.21 | 1.01 | 0.37 | 17.36 | 15.45 | 7.74 | 4.53 | 10.22 | 1.53 | 1066 | −3641.34 | −0.53 | −8.80 | 6.01 | −22455.00 | |
| 3.333 | 82.394 | 16.82 | 11.58 | 10.97 | 6.29 | 9.89 | 4.36 | 1.61 | 0.45 | 19.33 | 16.63 | 7.50 | 4.62 | 10.97 | 1.59 | 1332 | −4351.04 | −2.16 | −9.32 | 5.20 | −25795.60 | |
| 6.226 | 98.413 | 16.75 | 15.01 | 11.24 | 9.21 | 8.68 | 6.33 | 0.69 | 0.33 | 21.04 | 20.26 | 13.63 | 10.57 | 11.24 | 1.81 | 1740 | −3941.23 | −0.50 | −9.02 | 2.94 | −26585.40 | |
| 7.018 | 107.615 | 18.17 | 16.42 | 12.24 | 10.21 | 9.38 | 7.04 | 0.69 | 0.33 | 23.04 | 22.25 | 15.46 | 12.24 | 12.24 | 1.78 | 2276 | −4252.93 | −0.32 | −9.21 | 2.99 | −29711.10 | |
| 7.811 | 116.817 | 19.58 | 17.84 | 13.24 | 11.21 | 10.09 | 7.75 | 0.69 | 0.33 | 25.04 | 24.25 | 17.32 | 13.94 | 13.24 | 1.76 | 2912 | −4564.56 | −0.50 | −9.02 | 2.94 | −32956.10 | |
| 8.604 | 126.019 | 21.00 | 19.25 | 14.24 | 12.21 | 10.80 | 8.45 | 0.69 | 0.33 | 27.03 | 26.25 | 19.19 | 15.68 | 14.24 | 1.73 | 3656 | −4876.23 | −0.50 | −9.02 | 2.94 | −36224.10 | |
| 3.667 | 73.017 | 12.51 | 10.25 | 8.24 | 5.52 | 6.55 | 3.58 | 0.69 | 0.31 | 15.06 | 13.75 | 7.88 | 5.53 | 8.24 | 1.94 | 652 | −2948.97 | −0.59 | −8.78 | 5.12 | −15923.90 | |
| 4.352 | 82.793 | 14.21 | 11.48 | 9.75 | 6.47 | 8.14 | 4.44 | 0.90 | 0.41 | 16.37 | 14.58 | 7.68 | 5.00 | 9.75 | 1.43 | 1014 | −3332.84 | −0.77 | −8.81 | 5.03 | −19365.60 | |
| 4.411 | 77.591 | 13.67 | 11.25 | 9.16 | 6.22 | 7.96 | 4.53 | 1.09 | 0.56 | 15.39 | 13.85 | 6.55 | 3.95 | 9.16 | 1.50 | 814 | −3205.54 | −0.41 | −8.86 | 5.14 | −18787.40 | |
| 4.411 | 77.591 | 13.67 | 11.25 | 9.16 | 6.22 | 7.95 | 4.53 | 1.09 | 0.56 | 15.39 | 13.85 | 6.55 | 3.95 | 9.16 | 1.51 | 826 | −3205.57 | −0.37 | −9.12 | 5.42 | −18727.20 | |
| 3.438 | 85.476 | 15.95 | 12.99 | 10.63 | 6.86 | 8.95 | 4.76 | 1.21 | 0.53 | 18.34 | 16.72 | 8.11 | 4.68 | 10.63 | 1.56 | 1199 | −4001.38 | −0.37 | −9.10 | 6.54 | −24635.10 | |
| 3.851 | 87.199 | 17.69 | 12.70 | 11.38 | 6.81 | 10.41 | 4.91 | 1.80 | 0.61 | 20.31 | 17.90 | 7.89 | 4.77 | 11.38 | 1.62 | 1487 | −4711.35 | −2.16 | −9.53 | 4.96 | −28085.80 |
Correlation matrix for antibacterial activity of benzylidene hydrazides against S. aureus.
| pMICsa | log | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | Te | Ele.E | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pMICsa | 1.000 | ||||||||||||||
| log | 0.784 | 1.000 | |||||||||||||
| 0 | 0.923 | 0.822 | 1.000 | ||||||||||||
| 0 | 0.899 | 0.940 | 0.950 | 1.000 | |||||||||||
| 1 | 0.914 | 0.859 | 0.994 | 0.967 | 1.000 | ||||||||||
| 1 | 0.861 | 0.971 | 0.917 | 0.991 | 0.944 | 1.000 | |||||||||
| 2 | 0.864 | 0.636 | 0.941 | 0.808 | 0.916 | 0.749 | 1.000 | ||||||||
| 2 | 0.881 | 0.968 | 0.929 | 0.993 | 0.951 | 0.994 | 0.787 | 1.000 | |||||||
| 3 | −0.074 | −0.536 | −0.083 | −0.348 | −0.169 | −0.447 | 0.236 | −0.374 | 1.000 | ||||||
| 3 | −0.096 | −0.447 | −0.179 | −0.331 | −0.248 | −0.427 | 0.109 | −0.334 | 0.873 | 1.000 | |||||
| 0.901 | 0.920 | 0.965 | 0.991 | 0.975 | 0.982 | 0.822 | 0.978 | −0.323 | −0.365 | 1.000 | |||||
| 0.801 | 0.957 | 0.865 | 0.958 | 0.897 | 0.981 | 0.652 | 0.957 | −0.562 | −0.575 | 0.963 | 1.000 | ||||
| 0.760 | 0.953 | 0.827 | 0.931 | 0.863 | 0.965 | 0.599 | 0.935 | −0.613 | −0.631 | 0.938 | 0.996 | 1.000 | |||
| Te | −0.890 | −0.646 | −0.958 | −0.837 | −0.924 | −0.773 | −0.973 | −0.799 | −0.183 | −0.041 | −0.865 | −0.702 | −0.649 | 1.000 | |
| Ele.E | −0.925 | −0.823 | −0.999 | −0.954 | −0.993 | −0.920 | −0.936 | −0.932 | 0.091 | 0.180 | −0.967 | −0.867 | −0.827 | 0.956 | 1.000 |
Correlation of molecular descriptors with antimicrobial (antibacterial and antifungal) activity.
| Mol. descriptor | pMICsa | pMICbs | pMICec | pMICca | pMICan | pMICb | pMICf | pMICam |
|---|---|---|---|---|---|---|---|---|
| log | 0.796 | 0.757 | 0.681 | 0.097 | −0.796 | 0.784 | −0.369 | 0.129 |
| MR | 0.922 | 0.889 | 0.739 | 0.266 | −0.769 | 0.887 | −0.221 | 0.308 |
| 0 | 0.981 | 0.955 | 0.740 | 0.381 | −0.655 | 0.923 | −0.066 | 0.455 |
| 0 | 0.935 | 0.900 | 0.750 | 0.260 | −0.769 | 0.899 | −0.225 | 0.311 |
| 1 | 0.967 | 0.939 | 0.740 | 0.372 | −0.683 | 0.914 | −0.089 | 0.432 |
| 1 | 0.889 | 0.846 | 0.733 | 0.192 | −0.804 | 0.861 | −0.299 | 0.230 |
| 2 | 0.939 | 0.933 | 0.657 | 0.511 | −0.430 | 0.864 | 0.162 | 0.609 |
| 2 | 0.913 | 0.874 | 0.742 | 0.222 | −0.773 | 0.881 | −0.258 | 0.274 |
| 3 | −0.016 | 0.036 | −0.163 | 0.338 | 0.580 | −0.074 | 0.591 | 0.442 |
| 3 | −0.055 | 0.010 | −0.172 | 0.293 | 0.583 | −0.096 | 0.558 | 0.399 |
| 0.953 | 0.918 | 0.749 | 0.288 | −0.745 | 0.908 | −0.189 | 0.346 | |
| 0.823 | 0.774 | 0.698 | 0.120 | −0.844 | 0.804 | −0.378 | 0.135 | |
| 0.765 | 0.711 | 0.668 | 0.058 | −0.860 | 0.754 | −0.435 | 0.061 | |
| 0.939 | 0.900 | 0.752 | 0.244 | −0.778 | 0.901 | −0.243 | 0.298 | |
| 0.818 | 0.768 | 0.699 | 0.103 | −0.850 | 0.801 | −0.394 | 0.120 | |
| 0.770 | 0.716 | 0.674 | 0.055 | −0.863 | 0.760 | −0.439 | 0.060 | |
| 0.967 | 0.939 | 0.740 | 0.372 | −0.683 | 0.914 | −0.089 | 0.432 | |
| 0.320 | 0.273 | 0.348 | −0.300 | −0.589 | 0.342 | −0.564 | −0.276 | |
| 0.906 | 0.881 | 0.720 | 0.296 | −0.732 | 0.871 | −0.176 | 0.334 | |
| Te | −0.962 | −0.948 | −0.689 | −0.449 | 0.498 | −0.890 | −0.075 | −0.552 |
| Ele.E | −0.980 | −0.956 | −0.745 | −0.383 | 0.659 | −0.925 | 0.066 | −0.456 |
| LUMO | −0.090 | −0.131 | 0.019 | −0.270 | −0.386 | −0.055 | −0.429 | −0.381 |
| HOMO | −0.568 | −0.592 | −0.289 | −0.168 | 0.135 | −0.476 | −0.058 | −0.313 |
| −0.608 | −0.593 | −0.602 | 0.070 | 0.774 | −0.643 | 0.488 | 0.045 |
Comparison of observed and predicted antibacterial and antifungal activity obtained by ot-QSAR model.
| Comp. | pMICsa (Eq. | pMICbs (Eq. | pMICec (Eq. | pMICca (Eq. | pMICan (Eq. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Obs. | Pre. | Res. | Obs. | Pre. | Res. | Obs. | Pre. | Res. | Obs. | Pre. | Res. | Obs. | Pre. | Res. | |
| 1.38 | 1.39 | −0.01 | 1.30 | 1.38 | −0.08 | 1.38 | 1.45 | −0.07 | 1.21 | 1.59 | −0.38 | 1.21 | 1.32 | −0.11 | |
| 1.42 | 1.43 | −0.01 | 1.42 | 1.42 | 0.00 | 1.36 | 1.50 | −0.14 | 1.24 | 1.69 | −0.45 | 1.24 | 1.23 | 0.01 | |
| 1.46 | 1.47 | −0.01 | 1.46 | 1.46 | 0.00 | 1.50 | 1.55 | −0.05 | 1.76 | 1.79 | −0.03 | 0.86 | 1.15 | −0.29 | |
| 1.49 | 1.51 | −0.02 | 1.49 | 1.50 | −0.01 | 1.79 | 1.60 | 0.19 | 2.09 | 1.88 | 0.21 | 1.20 | 1.07 | 0.13 | |
| 1.23 | 1.26 | −0.03 | 1.23 | 1.26 | −0.03 | 1.23 | 1.29 | −0.06 | 0.93 | 1.30 | −0.37 | 1.54 | 1.57 | −0.03 | |
| 1.30 | 1.31 | −0.01 | 1.30 | 1.31 | −0.01 | 1.30 | 1.31 | −0.01 | 1.90 | 1.52 | 0.38 | 1.60 | 1.60 | 0.00 | |
| 1.28 | 1.30 | −0.02 | 1.28 | 1.29 | −0.01 | 1.28 | 1.29 | −0.01 | 1.88 | 1.50 | 0.38 | 1.58 | 1.66 | −0.08 | |
| 1.28 | 1.30 | −0.02 | 1.28 | 1.29 | −0.01 | 1.28 | 1.29 | −0.01 | 1.34 | 1.49 | −0.15 | 1.88 | 1.66 | 0.22 | |
| 1.36 | 1.36 | 0.00 | 1.36 | 1.36 | 0.00 | 1.36 | 1.36 | 0.00 | 1.96 | 1.63 | 0.33 | 1.66 | 1.62 | 0.04 | |
| 1.40 | 1.41 | −0.01 | 1.40 | 1.40 | 0.00 | 1.40 | 1.39 | 0.01 | 1.70 | 1.83 | −0.13 | 1.70 | 1.62 | 0.08 | |
| 1.43 | 1.41 | 0.02 | 1.43 | 1.41 | 0.02 | 1.80 | 1.48 | 0.32 | 1.73 | 1.66 | 0.07 | 1.43 | 1.35 | 0.08 | |
| 1.47 | 1.45 | 0.02 | 1.47 | 1.45 | 0.02 | 1.47 | 1.53 | −0.06 | 1.12 | 1.76 | −0.64 | 1.12 | 1.27 | −0.15 | |
| 1.50 | 1.50 | 0.00 | 1.49 | 1.49 | 0.00 | 1.50 | 1.58 | −0.08 | 2.10 | 1.86 | 0.24 | 1.27 | 1.19 | 0.08 | |
| 1.53 | 1.54 | −0.01 | 1.53 | 1.53 | 0.00 | 1.53 | 1.63 | −0.10 | 1.83 | 1.95 | −0.12 | 1.29 | 1.11 | 0.18 | |
| 1.30 | 1.29 | 0.01 | 1.30 | 1.28 | 0.02 | 1.30 | 1.32 | −0.02 | 1.60 | 1.37 | 0.23 | 1.50 | 1.58 | −0.08 | |
| 1.36 | 1.34 | 0.02 | 1.36 | 1.32 | 0.04 | 1.36 | 1.34 | 0.02 | 1.76 | 1.59 | 0.17 | 1.76 | 1.60 | 0.16 | |
| 1.34 | 1.32 | 0.02 | 1.34 | 1.32 | 0.02 | 1.34 | 1.32 | 0.02 | 1.34 | 1.57 | −0.23 | 1.51 | 1.65 | −0.14 | |
| 1.34 | 1.32 | 0.02 | 1.34 | 1.32 | 0.02 | 1.34 | 1.32 | 0.02 | 1.61 | 1.56 | 0.05 | 1.61 | 1.65 | −0.04 | |
| 1.41 | 1.39 | 0.02 | 1.41 | 1.39 | 0.02 | 1.41 | 1.39 | 0.02 | 2.01 | 1.70 | 0.31 | 1.56 | 1.62 | −0.06 | |
| 1.45 | 1.44 | 0.01 | 1.45 | 1.43 | 0.02 | 1.45 | 1.42 | 0.03 | 2.05 | 1.90 | 0.15 | 1.60 | 1.61 | −0.01 | |
Regression analysis and quality of correlation for modeling antibacterial and antifungal activity of synthesized benzylidene hydrazides.
| S. no. | QSAR model (pMIC=) | |||||
|---|---|---|---|---|---|---|
| 1. | −0.000012Ele.E + 1.087 | 20 | 0.980 | 0.951 | 0.017 | 446.56 |
| 2. | 0.0431 | 20 | 0.967 | 0.919 | 0.022 | 258.85 |
| 3. | 0.043 | 20 | 0.967 | 0.919 | 0.022 | 258.85 |
| 4. | −0.000011Te + 0.962 | 20 | 0.962 | 0.909 | 0.023 | 225.84 |
| 5. | 0.02950 | 20 | 0.955 | 0.906 | 0.026 | 185.42 |
| 6. | −0.00011Te + 0.956 | 20 | 0.948 | 0.886 | 0.028 | 159.12 |
| 7. | 0.042 | 20 | 0.939 | 0.858 | 0.030 | 133.33 |
| 8. | 0.0421 | 20 | 0.939 | 0.858 | 0.030 | 133.33 |
| 9. | 0.0370 | 20 | 0.750 | 0.463 | 0.103 | 23.13 |
| 10. | 0.027 | 20 | 0.749 | 0.474 | 0.104 | 22.94 |
| 11. | −0.000017Ele.E + 1.004 | 20 | 0.745 | 0.456 | 0.104 | 22.40 |
| 12. | 0.0702 | 20 | 0.742 | 0.456 | 0.105 | 22.03 |
| 13. | −0.00022Te + 0.829 | 20 | 0.494 | −0.033 | 0.320 | 4.535 |
| 14. | 0.0370 | 20 | 0.750 | 0.463 | 0.103 | 23.13 |
| 15. | 0.027 | 20 | 0.749 | 0.474 | 0.104 | 22.94 |
| 16. | −0.000017Ele.E + 1.004 | 20 | 0.745 | 0.456 | 0.104 | 22.40 |
| 17. | 0.0702 | 20 | 0.742 | 0.456 | 0.105 | 22.03 |
Comparison of observed and predicted antimicrobial activity obtained by mt-QSAR models.
| Comp. | pMICb (Eq. | pMICf (Eq. | pMICam (Eq. | pMICam MLR (Eq. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Obs. | Pre. | Res. | Obs. | Pre. | Res. | Obs. | Pre. | Res. | Obs. | Pre. | Res. | |
| 1.35 | 1.39 | −0.04 | 1.21 | 1.43 | −0.22 | 1.30 | 1.44 | −0.14 | 1.30 | 1.39 | −0.09 | |
| 1.40 | 1.44 | −0.04 | 1.24 | 1.43 | −0.19 | 1.34 | 1.47 | −0.13 | 1.34 | 1.42 | −0.08 | |
| 1.47 | 1.49 | −0.02 | 1.31 | 1.43 | −0.12 | 1.41 | 1.51 | −0.10 | 1.41 | 1.46 | −0.05 | |
| 1.59 | 1.53 | 0.06 | 1.65 | 1.43 | 0.22 | 1.61 | 1.54 | 0.07 | 1.61 | 1.49 | 0.12 | |
| 1.23 | 1.25 | −0.02 | 1.24 | 1.43 | −0.19 | 1.23 | 1.33 | −0.10 | 1.23 | 1.29 | −0.06 | |
| 1.30 | 1.32 | −0.02 | 1.75 | 1.50 | 0.25 | 1.48 | 1.41 | 0.07 | 1.48 | 1.42 | 0.06 | |
| 1.28 | 1.29 | −0.01 | 1.73 | 1.57 | 0.16 | 1.46 | 1.40 | 0.06 | 1.46 | 1.42 | 0.04 | |
| 1.28 | 1.29 | −0.01 | 1.61 | 1.57 | 0.04 | 1.41 | 1.40 | 0.01 | 1.41 | 1.42 | −0.01 | |
| 1.36 | 1.37 | −0.01 | 1.81 | 1.62 | 0.19 | 1.54 | 1.45 | 0.09 | 1.54 | 1.48 | 0.06 | |
| 1.40 | 1.42 | −0.02 | 1.70 | 1.83 | −0.13 | 1.52 | 1.52 | 0.00 | 1.52 | 1.59 | −0.07 | |
| 1.55 | 1.43 | 0.12 | 1.58 | 1.50 | 0.08 | 1.56 | 1.46 | 0.10 | 1.56 | 1.44 | 0.12 | |
| 1.47 | 1.48 | −0.01 | 1.12 | 1.50 | −0.38 | 1.33 | 1.50 | −0.17 | 1.33 | 1.47 | −0.14 | |
| 1.50 | 1.52 | −0.02 | 1.69 | 1.50 | 0.19 | 1.57 | 1.53 | 0.04 | 1.57 | 1.50 | 0.07 | |
| 1.53 | 1.57 | −0.04 | 1.56 | 1.50 | 0.06 | 1.54 | 1.57 | −0.03 | 1.54 | 1.54 | 0.00 | |
| 1.30 | 1.28 | 0.02 | 1.55 | 1.50 | 0.05 | 1.40 | 1.36 | 0.04 | 1.40 | 1.34 | 0.06 | |
| 1.36 | 1.33 | 0.03 | 1.76 | 1.57 | 0.19 | 1.52 | 1.44 | 0.08 | 1.52 | 1.46 | 0.06 | |
| 1.34 | 1.32 | 0.02 | 1.43 | 1.64 | −0.21 | 1.37 | 1.43 | −0.06 | 1.37 | 1.46 | −0.09 | |
| 1.34 | 1.32 | 0.02 | 1.61 | 1.64 | −0.03 | 1.45 | 1.43 | 0.02 | 1.45 | 1.46 | −0.01 | |
| 1.41 | 1.40 | 0.01 | 1.79 | 1.69 | 0.10 | 1.56 | 1.48 | 0.08 | 1.56 | 1.52 | 0.04 | |
| 1.45 | 1.45 | 0.00 | 1.83 | 1.90 | −0.07 | 1.60 | 1.55 | 0.05 | 1.60 | 1.63 | −0.03 | |
Fig. 1Structural requirements for the antimicrobial activity benzylidene/2-chlorobenzylidene hydrazides.
Cytotoxicity and antiviral activity of synthesized benzylidene hydrazides in HeLa cell cultures.
| Comp. | Cytotoxicity (μg/mL) | Antiviral EC50 | ||||||
|---|---|---|---|---|---|---|---|---|
| CC50 | Minimum cytotoxic conc. | Vesicular stomatitis virus | Coxsackie virus B4 | Respiratory syncytial virus | ||||
| Visual CPE score | MTS | Visual CPE score | MTS | Visual CPE score | MTS | |||
| 61.2 | 100 | 9 | 6.5 | >20 | >20 | >20 | >20 | |
| 64.0 | 100 | 12 | 13.2 | >20 | >20 | >20 | >20 | |
| DS-5000 | >100 | >100 | >100 | >100 | >100 | >100 | 4 | 1.7 |
| ( | >250 | >250 | >250 | >250 | >250 | >250 | >250 | >250 |
| Ribavirin (μM) | >250 | >250 | 25 | 17.2 | 112 | 73.1 | 10 | 6.6 |
50% Cytotoxic concentration, as determined by measuring the cell viability with the colorimetric formazan-based MTS assay.
Minimum compound concentration that causes a microscopically detectable alteration of normal cell morphology.
50% Effective concentration, or concentration producing 50% inhibition of virus-induced cytopathic effect, as determined by visual scoring of the CPE, or by measuring the cell viability with the colorimetric formazan-based MTS assay.